Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Position Increased by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,714,628 shares of the company’s stock after purchasing an additional 3,155 shares during the quarter. Vanguard Group Inc. owned 5.65% of Amphastar Pharmaceuticals worth $100,794,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. TD Private Client Wealth LLC boosted its stake in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after acquiring an additional 388 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares during the last quarter. KBC Group NV raised its stake in shares of Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in Amphastar Pharmaceuticals by 8.5% in the third quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after acquiring an additional 801 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Amphastar Pharmaceuticals by 8.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,195 shares of the company’s stock worth $379,000 after purchasing an additional 833 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st.

Insiders Place Their Bets

In related news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 6.2 %

NASDAQ AMPH opened at $25.23 on Thursday. The stock has a 50-day simple moving average of $29.06 and a 200 day simple moving average of $38.46. The company has a market capitalization of $1.20 billion, a PE ratio of 8.41, a P/E/G ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 12 month low of $23.36 and a 12 month high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.